DYRK2 and chronic myelogenous leukemia, BCR-ABL1 positive: This tumor-suppressor role of DYRK2 seems to be CML specific because all other leukemia subtypes tested exhibited naturally elevated protein levels of DYRK2 at basal conditions (72), suggesting alternate driving mechanisms for tumorigenesis.